IRVINE, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that members of management will be participating in two upcoming investor conferences.
|Event:||SunTrust 5th Annual Life Sciences Summit|
|Date:||Tuesday, May 7, 2019|
|Location:||Lotte New York Palace, NY|
|Event:||Bank of America Merrill Lynch Healthcare Conference 2019|
|Format:||Presentation and 1x1 Meetings|
|Date:||Tuesday, May 14, 2019|
|Location:||Encore Hotel, Las Vegas, NV|
An audio webcast of Evolus’s presentation at the Bank of America Merrill Lynch Healthcare Conference will be available on the investor relations section of Evolus’s website at investors.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau™ (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau™ is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.
Jeuveau™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Brian Johnston, The Ruth Group
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations